Type 2 diabetes
Metabolic· 20 reviewed drugs· 43663 cited findings behind them
What the regulatory reviews cover
The regulatory review documents in this library for Type 2 diabetes include several drugs with varying indications and reported outcomes. Invokana, for instance, showed a Reduction in renal composite endpoint (ESKD, doubling of serum creatinine, and renal death) of 0.66. Mounjaro demonstrated HbA1c effect sizes for tirzepatide vs placebo (GPGI) ranging from -1.33 to -1.56. Jardiance reported an HbA1c reduction (%) of -0.85 %. Rybelsus indicated a reduction in fasting glucose with semaglutide vs placebo of 22 %. It is important to note that different drugs were studied in different trials, and therefore, the figures presented are not head-to-head comparisons.
Other drugs reviewed for Type 2 diabetes include ertugliflozin, Victoza, Farxiga, dapagliflozin, Glyxambi, Tresiba, Ozempic, Saxenda, Zepbound, semaglutide, Trulicity, Steglatro, Forxiga, Kyinsu, Lyumjev, and Awiqli. These reviews detail various aspects of their efficacy and safety, such as changes in HbA1c, cardiovascular event reductions, and rates of adverse events. The specific results and comparators for each drug are detailed in their respective review documents.
The drugs — one cited result each
| Invokana Johnson & Johnson | Reduction in renal composite endpoint (ESKD, doubling of serum creatinine, and renal death): 0.66 Johnson & Johnson — Invokana FDA Review (NDA204042, SUPPL 32, p.14 |
| Mounjaro Eli Lilly and Company | HbA1c effect sizes for tirzepatide vs placebo (GPGI): -1.33 to -1.56 Eli Lilly and Company — Mounjaro FDA Review (NDA215866, ORIG, p.96 |
| ertugliflozin Merck & Co., Inc. | 3273 cited findings on the drug page → |
| Victoza NOVO NORDISK INC | 3204 cited findings on the drug page → |
| Jardiance Boehringer Ingelheim | HbA1c reduction (%): -0.85 % Boehringer Ingelheim — Jardiance EMA EPAR public assessment, p.50 |
| Farxiga AstraZeneca PLC | 3069 cited findings on the drug page → |
| dapagliflozin AstraZeneca PLC | 2783 cited findings on the drug page → |
| Rybelsus NOVO | reduction in fasting glucose with semaglutide vs placebo: 22 % NOVO — Semaglutide FDA Review (NDA213051, ORIG 1, 2019), p.23 |
| Glyxambi Boehringer Ingelheim | 2189 cited findings on the drug page → |
| Tresiba NOVO | 2078 cited findings on the drug page → |
| Ozempic NOVO | 2042 cited findings on the drug page → |
| Saxenda Novo Nordisk A S | 1994 cited findings on the drug page → |
| Zepbound Eli Lilly and Company | 1766 cited findings on the drug page → |
| semaglutide Novo Nordisk A S | 1501 cited findings on the drug page → |
| Trulicity Eli Lilly and Company | 1474 cited findings on the drug page → |
| Steglatro Merck & Co., Inc. | 1185 cited findings on the drug page → |
| Forxiga AstraZeneca PLC | 1142 cited findings on the drug page → |
| Kyinsu Novo Nordisk A S | 1105 cited findings on the drug page → |
| Lyumjev Eli Lilly and Company | 1091 cited findings on the drug page → |
| Awiqli Novo Nordisk A S | 1067 cited findings on the drug page → |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Metabolic research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.